SEVILLE, Spain — In this Healio Video Perspective from the Congress on Controversies in Ophthalmology, Patricia Udaondo, MD, PhD, highlights the meeting’s debate sessions on new anti-VEGF therapies.
She addressed treatment durability, maintenance of functional and anatomical outcomes, safety and reduced injection burden.
“We need to go deeper with this kind of analysis to understand the real benefit to the patient and the system,” she said.
Udaondo also discussed biosimilars, which are a cost-saving option but have not kept pace with newer, longer-acting anti-VEGFs.
“The